carmustine has been researched along with Lymphoma, Mantle-Cell in 24 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Lymphoma, Mantle-Cell: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma." | 2.73 | Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. ( Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M, 2007) |
| "Simultaneous bilateral spontaneous pneumothorax (SBSP) during high-dose chemotherapy has been described in patients with pulmonary involvement by malignancy, including sarcoma, trophoblastic tumor, non-seminomatous testicular cancer, and non-Hodgkin lymphoma." | 1.36 | Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease. ( Schneider, AE; Talmon, GA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Costes-Tertrais, D | 1 |
| Hueso, T | 2 |
| Gastinne, T | 2 |
| Thieblemont, C | 1 |
| Oberic, L | 1 |
| Bouabdallah, K | 2 |
| Garciaz, S | 2 |
| Tchernonog, E | 2 |
| Dartigeas, C | 1 |
| Ribrag, V | 1 |
| Fogarty, P | 1 |
| Casasnovas, RO | 2 |
| Houot, R | 2 |
| Delette, C | 2 |
| Malak, S | 2 |
| Fornecker, LM | 2 |
| Gressin, R | 2 |
| Damaj, G | 2 |
| Le Gouill, S | 2 |
| Durot, E | 1 |
| Tessoulin, B | 1 |
| Tournilhac, O | 1 |
| Gyan, E | 1 |
| Abraham, J | 1 |
| Delapierre, B | 1 |
| Peyrade, F | 1 |
| Lemal, R | 1 |
| Chantepie, S | 1 |
| Borel, C | 1 |
| Morello, R | 1 |
| Ibrahim, A | 1 |
| Bouabdallah, R | 1 |
| Doorduijn, JK | 1 |
| Zijlstra, JM | 1 |
| Lugtenburg, PJ | 1 |
| Kersten, MJ | 1 |
| Böhmer, LH | 1 |
| Minnema, MC | 1 |
| MacKenzie, MA | 1 |
| van Marwijk Kooij, R | 1 |
| de Jongh, E | 1 |
| Snijders, TJF | 1 |
| de Weerdt, O | 1 |
| van Gelder, M | 1 |
| Hoogendoorn, M | 1 |
| Leys, RBL | 1 |
| Kibbelaar, RE | 1 |
| de Jong, D | 1 |
| Chitu, DA | 1 |
| Van't Veer, MB | 1 |
| Kluin-Nelemans, HC | 1 |
| Tseng, YD | 1 |
| Stevenson, PA | 1 |
| Cassaday, RD | 1 |
| Cowan, A | 1 |
| Till, BG | 1 |
| Shadman, M | 1 |
| Graf, SA | 1 |
| Ermoian, R | 1 |
| Smith, SD | 1 |
| Holmberg, LA | 1 |
| Press, OW | 1 |
| Gopal, AK | 1 |
| Lavolé, J | 1 |
| Le Goff, M | 1 |
| Oudjit, A | 1 |
| Sogni, P | 1 |
| Mallet, V | 1 |
| Ng, ZY | 1 |
| Bishton, M | 1 |
| Ritchie, D | 1 |
| Campbell, R | 1 |
| Gilbertson, M | 1 |
| Hill, K | 1 |
| Ratnasingam, S | 1 |
| Schwarer, A | 1 |
| Manos, K | 1 |
| Shorten, S | 1 |
| Ng, M | 1 |
| Nelson, N | 1 |
| Xin, L | 1 |
| De Mel Widanalage, S | 1 |
| Sunny, T | 1 |
| Purtill, D | 1 |
| Poon, M | 1 |
| Johnston, A | 1 |
| Cochrane, T | 1 |
| Lee, HP | 1 |
| Hapgood, G | 1 |
| Tam, C | 1 |
| Opat, S | 1 |
| Hawkes, E | 1 |
| Seymour, J | 1 |
| Cheah, CY | 1 |
| William, BM | 2 |
| Allen, MS | 1 |
| Loberiza, FR | 1 |
| Bociek, RG | 1 |
| Bierman, PJ | 1 |
| Armitage, JO | 1 |
| Vose, JM | 1 |
| Kolstad, A | 2 |
| Laurell, A | 2 |
| Jerkeman, M | 2 |
| Grønbæk, K | 1 |
| Elonen, E | 3 |
| Räty, R | 2 |
| Pedersen, LB | 2 |
| Loft, A | 1 |
| Bogsrud, TV | 1 |
| Kimby, E | 2 |
| Hansen, PB | 1 |
| Fagerli, UM | 1 |
| Nilsson-Ehle, H | 2 |
| Lauritzsen, GF | 2 |
| Lehmann, AK | 1 |
| Sundstrom, C | 2 |
| Karjalainen-Lindsberg, ML | 2 |
| Ralfkiaer, E | 2 |
| Ehinger, M | 2 |
| Delabie, J | 2 |
| Bentzen, H | 2 |
| Schildt, J | 1 |
| Kostova-Aherdan, K | 1 |
| Frederiksen, H | 1 |
| Brown, Pde N | 1 |
| Geisler, CH | 2 |
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 2 |
| Skoetz, N | 1 |
| Berger, MD | 1 |
| Branger, G | 1 |
| Klaeser, B | 1 |
| Taleghani, BM | 1 |
| Novak, U | 1 |
| Banz, Y | 1 |
| Mueller, BU | 1 |
| Pabst, T | 1 |
| Caimi, PF | 1 |
| Silva Rondon, CH | 1 |
| Fu, P | 1 |
| Cooper, BW | 1 |
| Campagnaro, EL | 1 |
| Gerson, SL | 1 |
| Reese-Koc, J | 1 |
| Fox, R | 1 |
| Creger, RJ | 1 |
| de Lima, M | 1 |
| Lazarus, HM | 1 |
| Philippe, L | 1 |
| Helias, P | 1 |
| Puyraveau, M | 1 |
| Boulahdour, H | 1 |
| Deconinck, E | 1 |
| Daguindau, E | 1 |
| Engman, CA | 1 |
| Hill, JM | 1 |
| Meehan, KR | 1 |
| Crout, CA | 1 |
| Koh, LP | 1 |
| Gockerman, JP | 1 |
| Moore, JO | 1 |
| Decastro, C | 1 |
| Long, GD | 1 |
| Diehl, L | 1 |
| Gasparetto, C | 1 |
| Niedzwiecki, D | 1 |
| Edwards, J | 1 |
| Prosnitz, L | 1 |
| Horwitz, M | 1 |
| Chute, J | 1 |
| Morris, A | 1 |
| Davis, P | 1 |
| Beaven, A | 1 |
| Chao, NJ | 1 |
| Ali-Osman, F | 1 |
| Rizzieri, DA | 1 |
| Schneider, AE | 1 |
| Talmon, GA | 1 |
| Andersen, NS | 1 |
| Eriksson, M | 1 |
| Nordström, M | 1 |
| Kuittinen, O | 2 |
| Brown, P | 1 |
| Oinonen, R | 1 |
| Jantunen, E | 1 |
| Itälä, M | 1 |
| Lehtinen, T | 1 |
| Franssila, K | 1 |
| Wiklund, T | 1 |
| Nickenig, C | 1 |
| Dreyling, M | 1 |
| Hoster, E | 1 |
| Ludwig, WD | 1 |
| Dörken, B | 1 |
| Freund, M | 1 |
| Huber, C | 1 |
| Ganser, A | 1 |
| Trümper, L | 1 |
| Forstpointner, R | 1 |
| Unterhalt, M | 1 |
| Hiddemann, W | 1 |
| Krishnan, A | 1 |
| Nademanee, A | 1 |
| Fung, HC | 1 |
| Raubitschek, AA | 1 |
| Molina, A | 1 |
| Yamauchi, D | 1 |
| Rodriguez, R | 1 |
| Spielberger, RT | 1 |
| Falk, P | 1 |
| Palmer, JM | 1 |
| Forman, SJ | 1 |
| Christopeit, M | 1 |
| Haak, U | 1 |
| Behre, G | 1 |
| Decaudin, D | 1 |
| Brousse, N | 1 |
| Brice, P | 1 |
| Haioun, C | 1 |
| Bourhis, JH | 1 |
| Morel, P | 1 |
| Van Hoof, A | 1 |
| Souleau, B | 1 |
| Quesnel, B | 1 |
| Gisselbrecht, C | 1 |
| Josting, A | 1 |
| Reiser, M | 1 |
| Wickramanayake, PD | 1 |
| Rueffer, U | 1 |
| Draube, A | 1 |
| Söhngen, D | 1 |
| Tesch, H | 1 |
| Wolf, J | 1 |
| Diehl, V | 1 |
| Martínez, C | 1 |
| Carreras, E | 1 |
| Rovira, M | 1 |
| Urbano-Ispizua, A | 1 |
| Esteve, J | 1 |
| Perales, M | 1 |
| Fernández, F | 1 |
| Montserrat, E | 1 |
| Dreger, P | 1 |
| Martin, S | 1 |
| Kuse, R | 1 |
| Sonnen, R | 1 |
| Glass, B | 1 |
| Kröger, N | 1 |
| Parwaresch, R | 1 |
| Kneba, M | 1 |
| Schmitz, N | 1 |
| Haas, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment[NCT00514475] | Phase 2 | 160 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carmustine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph | 2009 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modal | 2002 |
11 trials available for carmustine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Com | 2020 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; | 2014 |
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2014 |
Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aut | 2016 |
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 2010 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmus | 2012 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophospham | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2008 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Mo | 2000 |
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2000 |
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cy | 2000 |
11 other studies available for carmustine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytar | 2022 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytar | 2020 |
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fema | 2018 |
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; C | 2018 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progres | 2019 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2014 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyta | 2015 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Mo | 2010 |
Late-onset neutropenia following viral bone marrow depression after rituximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2008 |
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; | 2000 |